Cannabics Pharmaceuticals Announces Start of Clinical Study in Israel for Cancer Patients

BETHESDA, MarylandMarch 22, 2016 /PRNewswire/ — Cannabics Pharmaceuticals Inc. (CNBX) today announced the start of a clinical study in Israel for cancer patients utilizing Cannabics’ SR Capsules. This is one of the world’s first clinical studies specifically examining the effect of cannabis utilizing a medically standardized edible delivery system.

This clinical study involves patients with advanced cancer and cancer anorexia cachexia syndrome (CACS), endpoints examined are weight gain appetite, quality of life and a marker for anti-cancer activity. Quality of life in patients with CACS is directly related to loss of appetite and loss of weight. This study examines the influence of Cannabics Pharmaceuticals SR capsules on both of these common effects of cancer and cancer treatment.

Secondary outcome measures are improvement in appetite, reduction in TNF-alpha level, safety assessment for early psychiatric side-effects, quality of life and evaluation of muscle strength.

These studies are being carried out by the prestigious Rambam Medical Center in northern Israel and under strict regulations of the Ministry of Health, by whom Cannabics Pharmaceuticals has been licensed since 2014.

Said Dr. Eyal Ballan, CTO of the Company, “We expect the clinical proof of safety and efficacy to be of imperative importance to the medical community and particularly to prescribing physicians. We anticipate that successful completion of these clinical studies utilizing Cannabics SR capsules will further scientifically legitimize the use of this standardized delivery mechanism in the eyes of the medical community.”

Cannabics SR is an extended release oil capsule that provides a safe, effective and reliable administration of medical grade cannabis. It is composed solely from food grade materials, recognized by the FDA as GRAS (Generally Regarded As Safe). Cannabics SR 10mg delivers a plateaued level of beneficial effects for 8-10 hours. The once per day oral dosing regimen offered by Cannabics SR allows patients a more consistent beneficial effect without the dizziness and dissociation commonly found with immediate release administration methods.

While this study is taking place in Israel, it is fully registered with the US NIH under “Cannabics Capsules as Treatment to Improve Cancer Related CACS in Advanced Cancer Patients”, Identifier NCT02359123, and may be found at

About Cannabics Pharmaceuticals Inc.

Cannabics Pharmaceuticals Inc. is a U.S public company with licensed R&D based in Israel dedicated to the development of palliative and personalized Anti-Cancer treatments harnessing the versatile therapeutic values of cannabinoids to create tailored therapies for cancer patients. Our integrated technology has created a successful medically standardized delivery system offering patients natural, reliable and safe therapy.


Certain statements contained in this release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to statements identified by words such as “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “targets,” “projects” and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company’s management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our latest 10-Q Report filed on January 22nd, 2016. We undertake no duty to update any forward-looking statement or any information contained in this press release or in other public disclosures at any time.